Literature DB >> 15247533

Dopamine dysregulation syndrome in Parkinson's disease.

Andrew H Evans1, Andrew J Lees.   

Abstract

PURPOSE OF REVIEW: Dopamine replacement therapy in Parkinson's disease ameliorates motor symptoms. However, it has recently been recognized that a small sub-group of patients suffer motor and behavioural disturbances attributable to taking quantities of medication well beyond the dose required to treat their motor disabilities. This review examines the phenomenology of dopamine dysregulation syndrome in relation to the current understanding of basal ganglia function and its impact on long-term management. RECENT
FINDINGS: Cortico-striato-thalamic circuits are implicated in the behavioural and motor disturbances associated with compulsive medication use in Parkinson's disease. Advances in understanding of the role of dopamine in psychostimulant addiction are important in helping to understand dopamine dysregulation.
SUMMARY: Recognition of dopamine dysregulation syndrome and characterization of its phenomenology supports the notion that the medication used to treat Parkinson's disease can disrupt basal ganglia mediated motor and behavioural functioning. Refinement of clinical strategies to predict, identify and manage this syndrome will aid the future treatment of motor and non-motor complications of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247533     DOI: 10.1097/01.wco.0000137528.23126.41

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  39 in total

1.  Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?

Authors:  Rupam Borgohain; Rukmini Mridula Kandadai; Afshan Jabeen; Meena A Kannikannan
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

Review 2.  Dopaminergic action beyond its effects on motor function: imaging studies.

Authors:  David J Brooks
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

3.  Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model.

Authors:  David J Brooks
Journal:  Wien Klin Wochenschr       Date:  2006-10       Impact factor: 1.704

4.  Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients.

Authors:  F Raudino; P Garavaglia; C Pianezzola; G Riboldazzi; S Leva; M Guidotti; G Bono
Journal:  Neurol Sci       Date:  2009-01-24       Impact factor: 3.307

Review 5.  Impulsive and compulsive behaviors in Parkinson's disease.

Authors:  B B Averbeck; S S O'Sullivan; A Djamshidian
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 6.  Antiparkinsonian medication and pathological gambling.

Authors:  Malcolm Lader
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 7.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

9.  Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration.

Authors:  Trinna L Cuellar; Tigwa H Davis; Peter T Nelson; Gabriel B Loeb; Brian D Harfe; Erik Ullian; Michael T McManus
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-02       Impact factor: 11.205

10.  Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive-compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease.

Authors:  Silvia Cabrini; Mario Baratti; Flavio Bonfà; Giulio Cabri; Elena Uber; Maurizio Avanzi
Journal:  Neurol Sci       Date:  2009-06-10       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.